For citations:
Kolbin A.S., Gomon Yu.M., Proskurin M.A., Balykina Yu.E. Efficacy of alectinib in comparison with lorlatinib in patients with ALK-positive non-small cell lung cancer: pharmacoeconomic study. FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2023;16(3):412-421. (In Russ.) https://doi.org/10.17749/2070-4909/farmakoekonomika.2023.210

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.